News ADA: Lilly makes its case for oral GLP-1 orforglipron Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.
News ADA: Novo continues effort to rehabilitate CagriSema Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.
News Grail plans FDA filing for cancer blood test after new trial Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
News FDA blocks trials that send US cells to 'hostile' countries The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.
News Biogen bids to extend use of Skyclarys to younger patients Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
News J&J says two drugs are better than one in pretreated myeloma Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face